Julio C Barredo1, Caroline Hastings2, Xiamin Lu3, Meenakshi Devidas4, Yichen Chen5, Daniel Armstrong1, Naomi Winick6, Brent Lee Wood7, Rochelle Yanofsky8, Mignon Loh9, Julie M Gastier-Foster10, Dean Thomas Jorstad11, Robert Marcus12, Kim Ritchey13, William L Carrol14, Stephen P Hunger15. 1. Division of Hematology and Oncology, Department of Pediatrics, Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, Florida. 2. Department of Hematology/Oncology, Children's Hospital & Research Center Oakland, Oakland, California. 3. University of Florida, Gainesville, Florida. 4. Biostatistics & Children's Oncology Group, University of Florida, Gainesville, Florida. 5. Children's Oncology Group, Gainesville, USA. 6. Department of Pediatrics, UT Southwestern, Dallas, Texas. 7. University of Washin, Seattle, Washington. 8. Cancer Care Manitoba, Winnipeg, Manitoba, Canada. 9. Helen Diller Family Comprehensive Cancer Center, UCSSF Medical Center-Parnassus, San Francisco, California. 10. Department of Pathology, Nationwide Children's Hospital, Columbus, Ohio. 11. Children's Hospital of Wisconsin, Milwaukee, Wisconsin. 12. Nemours Children's Clinic, Pensacola, Florida. 13. Department of Pediatric Hematology/Oncology, Children's Hospital of Pittsburgh of UPMC, Pittsburgh, Pennsylvania. 14. Department of Pediatrics, New York University School of Medicine, New York, New York. 15. Department of Pediatric Oncology, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania.
Abstract
BACKGROUND: The incidence of isolated testicular relapse (ITR) of acute lymphoblastic leukemia (ALL) has decreased with contemporary treatment strategies, but outcomes are suboptimal with a 58% 5-year overall survival (OS). This study aimed to improve outcome in patients with ITR of B-cell ALL (B-ALL) occurring after 18 months of first clinical remission using intensive systemic chemotherapy and to decrease long-term sequelae by limiting use of testicular radiation. PROCEDURE: Forty patients in first ITR of B-ALL were enrolled. Induction (dexamethasone, vincristine, daunorubicin, and intrathecal triple therapy) was preceded by one dose of high-dose methotrexate (MTX, 5 g/m2 ). Following induction, 25 of 26 patients who had persistent testicular enlargement underwent testicular biopsy. Eleven had biopsy-proven disease and received bilateral testicular radiation (24 Gy), whereas twenty-nine did not. RESULTS: Overall 5-year event-free survival (EFS)/OS was 65.0 ± 8.8%/73.1 ± 8.3%, with 5-year EFS 62.1 ± 11.0% vs. 72.7 ± 14.4% for patients who did not receive radiation therapy (XRT) (n = 29) compared with those who did (n = 11), respectively (P = 0.64). There were six second bone marrow relapses and six second ITRs. The proportion of second relapses was similar in the patients that received testicular radiation and those who did not. However, the 5-year OS was similar for patients who did not receive XRT (72.6 ± 10.2%) compared with those who did (72.7 ± 14.4%) (P = 0.85). CONCLUSIONS: A 5-year OS rate of 73.1 ± 8.3% was obtained in children with first ITR of B-ALL occurring after 18 months of CR1 (length of first clinical remission) using intensive chemotherapy and limiting testicular radiation.
BACKGROUND: The incidence of isolated testicular relapse (ITR) of acute lymphoblastic leukemia (ALL) has decreased with contemporary treatment strategies, but outcomes are suboptimal with a 58% 5-year overall survival (OS). This study aimed to improve outcome in patients with ITR of B-cell ALL (B-ALL) occurring after 18 months of first clinical remission using intensive systemic chemotherapy and to decrease long-term sequelae by limiting use of testicular radiation. PROCEDURE: Forty patients in first ITR of B-ALL were enrolled. Induction (dexamethasone, vincristine, daunorubicin, and intrathecal triple therapy) was preceded by one dose of high-dose methotrexate (MTX, 5 g/m2 ). Following induction, 25 of 26 patients who had persistent testicular enlargement underwent testicular biopsy. Eleven had biopsy-proven disease and received bilateral testicular radiation (24 Gy), whereas twenty-nine did not. RESULTS: Overall 5-year event-free survival (EFS)/OS was 65.0 ± 8.8%/73.1 ± 8.3%, with 5-year EFS 62.1 ± 11.0% vs. 72.7 ± 14.4% for patients who did not receive radiation therapy (XRT) (n = 29) compared with those who did (n = 11), respectively (P = 0.64). There were six second bone marrow relapses and six second ITRs. The proportion of second relapses was similar in the patients that received testicular radiation and those who did not. However, the 5-year OS was similar for patients who did not receive XRT (72.6 ± 10.2%) compared with those who did (72.7 ± 14.4%) (P = 0.85). CONCLUSIONS: A 5-year OS rate of 73.1 ± 8.3% was obtained in children with first ITR of B-ALL occurring after 18 months of CR1 (length of first clinical remission) using intensive chemotherapy and limiting testicular radiation.
Authors: Yousif Matloub; Bruce C Bostrom; Stephen P Hunger; Linda C Stork; Anne Angiolillo; Harland Sather; Mei La; Julie M Gastier-Foster; Nyla A Heerema; Scott Sailer; Patrick J Buckley; Blythe Thomson; Catherine Cole; James B Nachman; Gregory Reaman; Naomi Winick; William L Carroll; Meenakshi Devidas; Paul S Gaynon Journal: Blood Date: 2011-05-11 Impact factor: 22.113
Authors: Mikhail Roshal; Jonathan R Fromm; Stuart Winter; Kimberly Dunsmore; Brent L Wood Journal: Cytometry B Clin Cytom Date: 2010-05 Impact factor: 3.058
Authors: M M Wofford; S D Smith; J J Shuster; W Johnson; G R Buchanan; M D Wharam; A K Ritchey; D Rosen; M E Haggard; B L Golembe Journal: J Clin Oncol Date: 1992-04 Impact factor: 44.544
Authors: A Reiter; M Schrappe; W D Ludwig; W Hiddemann; S Sauter; G Henze; M Zimmermann; F Lampert; W Havers; D Niethammer Journal: Blood Date: 1994-11-01 Impact factor: 22.113
Authors: Eric C Larsen; Meenakshi Devidas; Si Chen; Wanda L Salzer; Elizabeth A Raetz; Mignon L Loh; Leonard A Mattano; Catherine Cole; Alisa Eicher; Maureen Haugan; Mark Sorenson; Nyla A Heerema; Andrew A Carroll; Julie M Gastier-Foster; Michael J Borowitz; Brent L Wood; Cheryl L Willman; Naomi J Winick; Stephen P Hunger; William L Carroll Journal: J Clin Oncol Date: 2016-04-25 Impact factor: 44.544
Authors: Glen Lew; Yichen Chen; Xiaomin Lu; Susan R Rheingold; James A Whitlock; Meenakshi Devidas; Caroline A Hastings; Naomi J Winick; William L Carroll; Brent L Wood; Michael J Borowitz; Michael A Pulsipher; Stephen P Hunger Journal: Haematologica Date: 2021-01-01 Impact factor: 9.941
Authors: Bianca A W Hoeben; Jeffrey Y C Wong; Lotte S Fog; Christoph Losert; Andrea R Filippi; Søren M Bentzen; Adriana Balduzzi; Lena Specht Journal: Front Pediatr Date: 2021-12-03 Impact factor: 3.418
Authors: Seok Young Koh; Seunghyun Lee; Seul Bi Lee; Yeon Jin Cho; Young Hun Choi; Jung-Eun Cheon; Woo Sun Kim Journal: Ultrasonography Date: 2021-09-06
Authors: Caroline Hastings; Yichen Chen; Meenakshi Devidas; A Kim Ritchey; Naomi J Winick; William L Carroll; Stephen P Hunger; Brent L Wood; Robert B Marcus; Julio C Barredo Journal: Pediatr Blood Cancer Date: 2021-07-24 Impact factor: 3.838
Authors: Marsida Hutka; Lee B Smith; Ellen Goossens; W Hamish B Wallace; Jan-Bernd Stukenborg; Rod T Mitchell Journal: J Clin Med Date: 2020-01-18 Impact factor: 4.241
Authors: Nikolaos Tsagkas; Androniki Troussa; George Vorgias; Olympia Tzaida; Nektaria Zagorianakou; Maria Gonidi Journal: Case Rep Obstet Gynecol Date: 2020-08-31